Keynote Speakers

 Sunday, March 11th – 8:30-9:30 am

Dr. Jedd Wolchok

Dr. Jedd Wolchok

Topic:  Immunologic checkpoint blockade: Exploring combinations and mechanisms

Dr. Wolchok is chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK). His insight and innovation have placed him at the leading edge of cancer immunotherapy in two different roles:  An active clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma. He’s been involved in the development of the DNA vaccine program at every level – from initial studies in mouse models, through all levels of regulatory review, and now as principal investigator of the clinical trials.

I couldn’t be more happy and honored to have Dr. Jedd Wolchok from Sloan-Kettering be our keynote speaker for the mid-year meeting on cancer immunotherapy,” said Dr. Phil Bergman.  “Jedd has been instrumental to the human cancer immunotherapy field for decades and especially the last 7 years with his seminal work on multiple checkpoint inhibitor monoclonal antibodies that are now FDA approved and revolutionizing the treatment of human cancers. I met and worked with Jedd starting 18 years ago on the melanoma vaccine and he is now one of the most sought after speakers on human cancer immunotherapy, so it is a real treat that he will provide us our keynote lecture.”